Wieke Hm Verbeek

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. ncbi request reprint Novel approaches in the management of refractory celiac disease
    Wieke Hm Verbeek
    VU University Medical Center, Department of Gastroenterology and Hepatology, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
    Expert Rev Clin Immunol 4:205-19. 2008
  2. doi request reprint Aberrant T-lymphocytes in refractory coeliac disease are not strictly confined to a small intestinal intraepithelial localization
    W H M Verbeek
    Department of Gastroenterology, VU University Medical Centre, Amsterdam, The Netherlands
    Cytometry B Clin Cytom 76:367-74. 2009
  3. doi request reprint Incidence of enteropathy--associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands
    Wieke H M Verbeek
    Department of Gastroenterology, VU University Medical Centre, Amsterdam, The Netherlands
    Scand J Gastroenterol 43:1322-8. 2008
  4. ncbi request reprint Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in Refractory Celiac Disease
    Wieke H M Verbeek
    Department of Gastroenterology, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands
    Clin Immunol 126:48-56. 2008
  5. ncbi request reprint Decreased circulating iNKT cell numbers in refractory coeliac disease
    David Bernardo
    Mucosal Immunology Lab, Department of Paediatrics and Immunology IBGM, University of Valladolid, Valladolid, Spain
    Clin Immunol 126:172-9. 2008
  6. ncbi request reprint The MYO9B gene is a strong risk factor for developing refractory celiac disease
    Victorien M Wolters
    Department of Pediatric Gastroenterology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Clin Gastroenterol Hepatol 5:1399-405, 1405.e1-2. 2007
  7. pmc Newly identified genetic risk variants for celiac disease related to the immune response
    Karen A Hunt
    Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, 4 Newark Street, London E1 2AT, UK
    Nat Genet 40:395-402. 2008
  8. ncbi request reprint Update on the management of refractory coeliac disease
    Abdulbaqi Al-Toma
    Department of Gastroenterology, VU University Medical Center, Amsterdam, The Netherlands
    J Gastrointestin Liver Dis 16:57-63. 2007
  9. ncbi request reprint Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells
    Abdulbaqi Al-Toma
    Department of Gastroenterology, VU University Medical Center, Amsterdam, The Netherlands
    Blood 109:2243-9. 2007
  10. ncbi request reprint Alemtuzumab for refractory celiac disease
    Wieke H M Verbeek
    N Engl J Med 355:1396-7; author reply 1397. 2006

Collaborators

  • Chris J J Mulder
  • Muhammed Hadithi
  • V M H Coupe
  • S Daum
  • Otto J Visser
  • Hetty J Bontkes
  • José Antonio Garrote
  • D S Sanders
  • M C Wapenaar
  • Maria Luisa Mearin
  • Peter D Howdle
  • J J Oudejans
  • Julian R Walters
  • Abdulbaqi Al-Toma
  • David Bernardo
  • Karen A Hunt
  • Marco W J Schreurs
  • B Mary E von Blomberg
  • Alexandra Zhernakova
  • Cisca Wijmenga
  • Victorien M Wolters
  • Ralph McGinnis
  • Dermot Kelleher
  • Davinder Panesar
  • Geoffrey K T Holmes
  • Fumihiko Takeuchi
  • Anthony W Ryan
  • Graham A R Heap
  • Gosia Trynka
  • A Salvador Pena
  • Panos Deloukas
  • Marcel Bruinenberg
  • Rik J Scheper
  • Ingrid M W van Hoogstraten
  • Graham Turner
  • Charles A Mein
  • Nicholas P Kennedy
  • David P Strachan
  • Lotte C Dinesen
  • William M McLaren
  • Raymond J Playford
  • Valerie Trimble
  • Wendy L McArdle
  • Jihane Romanos
  • Eduardo Arranz
  • Colm O'Morain
  • Fiona M Stevens
  • Daniel J Pennington
  • Rhian Gwilliam
  • Ross McManus
  • Lude Franke
  • David A van Heel
  • Willem Verduijn
  • Alienke J Monsuur
  • Charlotte Onland-Moret
  • Hyacintha M van Roessel
  • Petra E T Scholten
  • Peter C Huijgens
  • Gert J Ossenkoppele

Detail Information

Publications10

  1. ncbi request reprint Novel approaches in the management of refractory celiac disease
    Wieke Hm Verbeek
    VU University Medical Center, Department of Gastroenterology and Hepatology, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
    Expert Rev Clin Immunol 4:205-19. 2008
    ..Although management of these patients is difficult and therapeutic options are currently limited, novel treatment modalities are being explored...
  2. doi request reprint Aberrant T-lymphocytes in refractory coeliac disease are not strictly confined to a small intestinal intraepithelial localization
    W H M Verbeek
    Department of Gastroenterology, VU University Medical Centre, Amsterdam, The Netherlands
    Cytometry B Clin Cytom 76:367-74. 2009
    ....
  3. doi request reprint Incidence of enteropathy--associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands
    Wieke H M Verbeek
    Department of Gastroenterology, VU University Medical Centre, Amsterdam, The Netherlands
    Scand J Gastroenterol 43:1322-8. 2008
    ..The aim of this study was to investigate the incidence of EATL and the demographic characteristics of patients with EATL in The Netherlands...
  4. ncbi request reprint Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in Refractory Celiac Disease
    Wieke H M Verbeek
    Department of Gastroenterology, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands
    Clin Immunol 126:48-56. 2008
    ..Early detection of those patients that actually develop EATL is of utmost importance for curative intervention...
  5. ncbi request reprint Decreased circulating iNKT cell numbers in refractory coeliac disease
    David Bernardo
    Mucosal Immunology Lab, Department of Paediatrics and Immunology IBGM, University of Valladolid, Valladolid, Spain
    Clin Immunol 126:172-9. 2008
    ..Some of these patients exhibit a high risk to develop enteropathy-associated T-cell lymphoma (EATL)...
  6. ncbi request reprint The MYO9B gene is a strong risk factor for developing refractory celiac disease
    Victorien M Wolters
    Department of Pediatric Gastroenterology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Clin Gastroenterol Hepatol 5:1399-405, 1405.e1-2. 2007
    ..HLA-DQ2 homozygosity is associated with complications of CD such as refractory celiac disease type II (RCD II) and enteropathy-associated T-cell lymphoma (EATL). We investigated whether MYO9B also predisposes to RCD II and EATL...
  7. pmc Newly identified genetic risk variants for celiac disease related to the immune response
    Karen A Hunt
    Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, 4 Newark Street, London E1 2AT, UK
    Nat Genet 40:395-402. 2008
    ..Type 1 diabetes and celiac disease share HLA-DQ, IL2-IL21, CCR3 and SH2B3 risk regions. Thus, this extensive genome-wide association follow-up study has identified additional celiac disease risk variants in relevant biological pathways...
  8. ncbi request reprint Update on the management of refractory coeliac disease
    Abdulbaqi Al-Toma
    Department of Gastroenterology, VU University Medical Center, Amsterdam, The Netherlands
    J Gastrointestin Liver Dis 16:57-63. 2007
    ..This review provides an overview of the currently available diagnostic and therapeutic methods in a complicated form of coeliac disease...
  9. ncbi request reprint Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells
    Abdulbaqi Al-Toma
    Department of Gastroenterology, VU University Medical Center, Amsterdam, The Netherlands
    Blood 109:2243-9. 2007
    ..These preliminary results showed that high-dose chemotherapy followed by ASCT seems feasible and safe and might result in long-term improvement of patients with RCD type II whose condition did not respond promptly to available drugs...
  10. ncbi request reprint Alemtuzumab for refractory celiac disease
    Wieke H M Verbeek
    N Engl J Med 355:1396-7; author reply 1397. 2006